Opus Genetics Inc Dossier - Source-backed chat

Opus Genetics Inc

IRDNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.75

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.51Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $375.2M

Enterprise Value $287.6M

Shares Outstanding 83.2M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Opus Genetics, Inc. (NASDAQ: IRD) represents a highly compelling, clinical-stage investment opportunity in the inherited retinal disease (IRD) gene therapy space. Following its transformative merger with Ocuphire Pharma in late 2024, the company has successfully consolidated late-stage ophthalmic development expertise with a robust, multi-asset AAV-based gene therapy pipeline. Backed by the Foundation Fighting Blindness and its Retinal Degeneration Fund, Opus is uniquely positioned to address rare, orphan causes of blindness that have historically been overlooked. The company's lead asset, OPGx-LCA5, has demonstrated robust, durable visual restoration in clinical trials, and its acceptance into the FDA's Rare Disease Evidence Principles (RDEP) program paves the way for a highly streamlined, cost-effective single pivotal Phase 3 trial starting in Q4 2026. With a recently secured $155 million strategic financing facility from Oberland Capital, the company's cash runway is extended into 2029, fully funding multiple high-impact clinical readouts and potential product approvals without immediate dilution concerns.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets18 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$10.56

High · most bullish analyst$16.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case considers potential clinical or regulatory setbacks, such as safety concerns or insufficient efficacy in the upcoming OPGx-BEST1 readout, or delays in initiating the OPGx-LCA5 Phase 3 trial. Additionally, if the FDA requests additional clinical trials beyond the single pivotal study planned under the RDEP program, the company's cash burn would accelerate, potentially exhausting its cash runway earlier than 2029 and necessitating dilutive equity raises.

Base CaseCentral scenario

The base case assumes successful execution of the OPGx-LCA5 Phase 3 trial starting in Q4 2026, with positive topline data from the OPGx-BEST1 Phase 1/2 trial in September 2026. It also projects the successful entry of OPGx-RDH12, OPGx-MERTK, and OPGx-RHO into clinical trials over the next 12 to 18 months. Under this scenario, the company leverages its streamlined regulatory pathways and non-dilutive funding partnerships to advance its pipeline toward commercialization, achieving significant valuation inflection points as clinical milestones are met.

Bull CaseUpside scenario

The bull case for Opus Genetics centers on its promising scientific platform utilizing one-dose AAV gene augmentations to treat inherited retinal diseases (IRDs). Key drivers include: (1) OPGx-LCA5, its lead candidate for LCA5-associated IRD, which demonstrated encouraging safety and visual improvements in Phase 1/2 trials and has aligned with the FDA on a Phase 3 registrational trial design; (2) OPGx-BEST1, which is in Phase 1/2 clinical testing with initial data readouts serving as a platform validation event; and (3) a strong balance sheet with over $50 million in cash (following a Series B preferred stock private placement in early 2026) providing a runway into the first half of 2028.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Robust, multi-asset AAV-based gene therapy pipeline targeting high-unmet-need inherited retinal diseases.
Lead program OPGx-LCA5 accepted into the FDA's Rare Disease Evidence Principles (RDEP) program, enabling a streamlined single pivotal Phase 3 trial.
Strong financial backing with a $155 million Oberland Capital facility, extending the cash runway into 2029.
Deep strategic relationships with patient advocacy groups (e.g., Foundation Fighting Blindness, RDH12 Alliance) providing non-dilutive funding and patient registry access.
Potential to secure valuable Priority Review Vouchers (PRVs) upon regulatory approvals.

Key Investment Risks

Clinical development risk inherent to early-stage gene therapies, including potential safety or efficacy hurdles.
Regulatory risks if the FDA or other global regulators require larger or longer clinical trials than currently anticipated.
Execution risks associated with manufacturing scale-up and specialized subretinal delivery of AAV vectors.
Dependence on milestone achievements to unlock additional tranches of the Oberland Capital financing facility.

Thesis Invalidation Triggers

Failure of OPGx-BEST1 to show clear efficacy or safety in the September 2026 topline data readout.
Significant delays in initiating the OPGx-LCA5 Phase 3 trial beyond Q4 2026.
Inability to meet the clinical milestones required to access additional funding tranches from Oberland Capital, leading to premature cash depletion.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.